A novel differential diagnostic model for multiple primary lung cancer: Differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasis

Chen,Dali; Mei,Longyong; Zhou,Yubin; Shen,Cheng; Xu,Huan; Niu,Zhongxi; Che,Guowei

doi:10.3892/ol.2015.2880

A novel differential diagnostic model for multiple primary lung cancer: Differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasis

Authors:
- Dali Chen
- Longyong Mei
- Yubin Zhou
- Cheng Shen
- Huan Xu
- Zhongxi Niu
- Guowei Che
View Affiliations

Affiliations: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China, Department of Thoracic Surgery, Daping Hospital, The Third Military Medical University, Chongqing, P.R. China, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China
Published online on: January 15, 2015 https://doi.org/10.3892/ol.2015.2880
Pages: 1081-1088
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of synchronous multiple primary lung cancer (MPLC) is increasing. However, present diagnostic methods are unable to satisfy the individualized treatment requirements of patients with MPLC. The present study aimed to establish a quantitative mathematical model and analyze its diagnostic value for distinguishing between MPLC and cases of the histologically similar disease, intrapulmonary metastasis (IPM). The sum value of the differential expression ratios of four proteins, namely p53, p16, p27 and c‑erbB2, was evaluated by immunohistochemically‑staining specimens of primary cancers, second separate cancers, metastatic lymph nodes and metastatic cancers. The sum value of the differential expression ratio of the four proteins from the primary tumor and the lymph‑node metastasis or metastatic cancer was <90 in the 11 patients with a single metastatic cancer and in the 30 patients with lymph‑node metastasis, but was >90 in the 14 patients with different histological types of MPLC. Therefore, a quantitative differentially‑expressed gene mathematical model was established as follows: Sum of the differential expression ratios = p16T1 - T + p27T1 ‑ T2 + C‑erbB2T1 ‑ T2 + p53T1 ‑ T2, where T1 is the primary cancer and T2 is the lymph node metastasis, metastatic cancer or the second separate cancer. The quantitative differentially‑expressed gene mathematical model is considered to be a useful tool for distinguishing between MPLC and IPM.

View Figures

View References

1	Ferguson MK, DeMeester TR, DesLauriers J, et al: Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg. 89:378–385. 1985.PubMed/NCBI
2	Adebonojo SA, Moritz DM and Danby CA: The results of modern surgical therapy for multiple primary lung cancers. Chest. 112:693–701. 1997. View Article : Google Scholar : PubMed/NCBI
3	Martini N and Melamed MR: Multiple primary lung cancers. J Thorac Cardiovasc Surg. 70:606–612. 1975.PubMed/NCBI
4	Sugio K, Kishimoto Y, Virmani AK, et al: K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 54:5811–5815. 1994.PubMed/NCBI
5	Kishimoto Y, Sugio K, Hung JY, et al: Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst. 87:1224–1229. 1995. View Article : Google Scholar : PubMed/NCBI
6	Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD and Gazdar AF: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 18:643–650. 1999. View Article : Google Scholar : PubMed/NCBI
7	Aoyagi Y, Yokose T, Minami Y, et al: Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res. 61:7950–7954. 2001.PubMed/NCBI
8	Strong MS, Incze J and Vaughan CW: Field cancerization in the aerodigestive tract - its etiology, manifestation, and significance. J Otolaryngol. 13:1–6. 1984.PubMed/NCBI
9	Matsuzoe D, Hideshima T, Ohshima K, et al: Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation. Br J Cancer. 79:1549–1552. 1999. View Article : Google Scholar : PubMed/NCBI
10	Hiroshima K, Toyozaki T, Kohno H, Ohwada H and Fujisawa T: Synchronous and metachronous lung carcinomas: molecular evidence for multicentricity. Pathol Int. 48:869–876. 1998. View Article : Google Scholar : PubMed/NCBI
11	Mitsudomi T, Yatabe Y, Koshikawa T, et al: Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. J Thorac Cardiovasc Surg. 114:354–360. 1997. View Article : Google Scholar : PubMed/NCBI
12	Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
13	Tsukamoto S, Sugio K, Sakada T, et al: Reduced expression of cell-cycle regulator p27 (Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer. 34:83–90. 2001. View Article : Google Scholar : PubMed/NCBI
14	Osaki T, Mitsudomi T, Oyama T, Nakanishi R and Yasumoto K: Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest. 108:157–162. 1995. View Article : Google Scholar : PubMed/NCBI
15	Dobashi K, Sugio K, Osaki T, Oka T and Yasumoto K: Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg. 114:339–346. 1997. View Article : Google Scholar : PubMed/NCBI
16	Taga S, Osaki T, Ohgami A, et al: Prognostic value of the immunohistochemical detection of p16INK4 expression in non small cell lung carcinoma. Cancer. 80:389–395. 1997. View Article : Google Scholar : PubMed/NCBI
17	Pommier RF, Vetto JT, Lee JT and Johnston KM: Synchronous non-small cell lung cancers. Am J Surg. 171:521–524. 1996. View Article : Google Scholar : PubMed/NCBI
18	Mathisen DJ, Jensik RJ, Faber LP and Kittle CF: Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg. 88:502–510. 1984.PubMed/NCBI
19	Rosengart TK, Martini N, Ghosn P and Burt M: Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg. 52:773–779. 1991. View Article : Google Scholar : PubMed/NCBI
20	Lau DH, Yang B, Hu R and Benfield JR: Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis. Diagn Mol Pathol. 6:179–184. 1997. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Christiani DC, Mark EJ, et al: Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multipleprimary lung carcinoma. Cancer. 85:1734–1739. 1999. View Article : Google Scholar : PubMed/NCBI
22	Ribeiro U, Safatle-Ribeiro AV, Posner MC, et al: Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. Surgery. 120:45–53. 1996. View Article : Google Scholar : PubMed/NCBI
23	Leong PP, Rezai B, Koch WM, et al: Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 90:972–977. 1998. View Article : Google Scholar : PubMed/NCBI
24	Califano J, Leong PL, Koch WM, et al: Second esophageal tumors in patients with head and neck squamous cell carcinoma: an assessment of clonal relationships. Clin Cancer Res. 5:1862–1867. 1999.PubMed/NCBI
25	van Oijen MG, Leppers Vd Straat FG, Tilanus MG and Slootweg PJ: The origins of multiple squamous cell carcinoma in the aerodigestive tract. Cancer. 88:884–893. 2000. View Article : Google Scholar : PubMed/NCBI
26	Shimizu S, Yatabe Y, Koshikawa T, et al: High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res. 6:3994–3999. 2000.PubMed/NCBI
27	Sozzi G, Miozzo M, Pastorino U, et al: Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res. 55:135–140. 1995.PubMed/NCBI
28	van der Sijp JR, van Meerbeeck JP, Maat AP, et al: Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. J Clin Oncol. 20:1105–1114. 2002. View Article : Google Scholar : PubMed/NCBI
29	Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS and Lee YC: Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res. 13:52–58. 2007. View Article : Google Scholar : PubMed/NCBI
30	Mitsudomi T, Hamajima N, Ogawa M and Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 6:4055–4063. 2000.PubMed/NCBI
31	Mogi A and Kuwano H: TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011:5839292011. View Article : Google Scholar : PubMed/NCBI
32	Sasai K, Sukezane T, Yanagita E, et al: Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo. Cancer Res. 71:2541–2549. 2011. View Article : Google Scholar : PubMed/NCBI
33	Iwakawa R, Kohno T, Anami Y, et al: Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin Cancer Res. 14:3746–3753. 2008. View Article : Google Scholar : PubMed/NCBI
34	Otterson GA, Kratzke RA, Coxon A, Kim YW and Kaye FJ: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. 9:3375–3378. 1994.PubMed/NCBI
35	Lou-Qian Z, Rong Y, Ming L, et al: The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One. 8:e549702013. View Article : Google Scholar : PubMed/NCBI
36	Esposito V, Baldi A, De Luca A, et al: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:3381–3385. 1997.PubMed/NCBI
37	Catzavelos C, Tsao MS, DeBoer G, et al: Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 59:684–688. 1999.PubMed/NCBI
38	Zhuang Y, Yin HT, Yin XL, Wang J and Zhang DP: High p27 expression is associated with a better prognosis in East Asian non-small cell lung cancer patients. Clin Chim Acta. 412:2228–2231. 2011. View Article : Google Scholar : PubMed/NCBI
39	Kristiansen G, Yu Y, Petersen S, et al: Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer. 37:1089–1095. 2001. View Article : Google Scholar : PubMed/NCBI
40	Turken O, Kunter E, Cermik H, Isitmangil T, Kandemir G, Yaylaci M and Ozturk A: Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). Neoplasma. 50:257–261. 2003.PubMed/NCBI
41	Gazdar AF and Minna JD: Multifocal lung cancers - clonality vs field cancerization and does it matter? J Natl Cancer Inst. 101:541–543. 2009. View Article : Google Scholar : PubMed/NCBI
42	Dali C, Huan X and Guowei C: Differential diagnosis of multiple tumor: multiple primary cancer or metastatic cancer of lung. Chin J Cancer Prev Treat. 9:721–724. 2014.